Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Jinn

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neurobiology of Aging|July 5, 2021
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial inductionRenee C Gentzel, Dawn Toolan, Sarah Jinn, et al.
Human Molecular Genetics|July 2, 2019
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson diseaseSarah Jinn, Cornelis Blauwendraat, Dawn Toolan, et al.
The Journal of Biological Chemistry|November 1, 2013
Box C/D small nucleolar RNA (snoRNA) U60 regulates intracellular cholesterol traffickingKatrina A Brandis, Sarah Gale, Sarah Jinn, et al.
Cell Metabolism|May 19, 2015
snoRNA U17 regulates cellular cholesterol traffickingSarah Jinn, Katrina A Brandis, Aileen Ren, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2017
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregationSarah Jinn, Robert E Drolet, Paige E Cramer, et al.
Neurobiology of Disease|July 10, 2025
Glucosylsphingosine is a potential fluid-based biomarker of lysosomal dysfunction in Cln3<sup>Δex7/8</sup> miceHallie Wald, Stephanie Cicalese, Lihang Yao, et al.
Neurobiology of Disease|September 12, 2021
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathyMali Cosden, Sarah Jinn, Lihang Yao, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neurobiology of Aging|July 5, 2021
Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial inductionRenee C Gentzel, Dawn Toolan, Sarah Jinn, et al.
Human Molecular Genetics|July 2, 2019
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson diseaseSarah Jinn, Cornelis Blauwendraat, Dawn Toolan, et al.
The Journal of Biological Chemistry|November 1, 2013
Box C/D small nucleolar RNA (snoRNA) U60 regulates intracellular cholesterol traffickingKatrina A Brandis, Sarah Gale, Sarah Jinn, et al.
Cell Metabolism|May 19, 2015
snoRNA U17 regulates cellular cholesterol traffickingSarah Jinn, Katrina A Brandis, Aileen Ren, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2017
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregationSarah Jinn, Robert E Drolet, Paige E Cramer, et al.
Neurobiology of Disease|July 10, 2025
Glucosylsphingosine is a potential fluid-based biomarker of lysosomal dysfunction in Cln3<sup>Δex7/8</sup> miceHallie Wald, Stephanie Cicalese, Lihang Yao, et al.
Neurobiology of Disease|September 12, 2021
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathyMali Cosden, Sarah Jinn, Lihang Yao, et al.
ACS Medicinal Chemistry Letters|January 17, 2024
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose ProjectionsH Marie Loughran, Kathy M Schirripa, Anthony J Roecker, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's DiseaseAnthony J Roecker, Kathy M Schirripa, H Marie Loughran, et al.
Pageof 1